Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News MaxCyte Inc MXCT

Technology Scientific & Technical Instruments
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MXCT)

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire 12 days ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

GlobeNewswire April 2, 2024

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

GlobeNewswire March 12, 2024

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

GlobeNewswire March 4, 2024

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

GlobeNewswire February 9, 2024

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

GlobeNewswire January 30, 2024

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

GlobeNewswire January 23, 2024

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire January 8, 2024

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

GlobeNewswire January 3, 2024
View More News ››

Opinion & Analysis (NDAQ:MXCT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MXCT)

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform

Breaking News: $MXCT MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to&#xA0;Advance Next Generation Cellular...
whytestocks - July 10, 2023

MAXCYTE: A PIONEER IN THE CELL THERAPY MARKET

  $MXCT Excited to share an article about MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering-focused...
AviseAnalytics - April 17, 2023
View more Bullboard ››

Good Natured Products Inc.

Good Natured Products Inc.

good natured Products Inc. offers an assortment of plant-based products made all, or in part, from the maximum possible ...
View More »